Senti Biosciences: Bayer entities report 6.9% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Senti Biosciences Holdings, Inc. is the issuer in an amended ownership report in which Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel each report beneficial ownership of 6,142,848 shares, or 6.90% of its common stock. The reported amount includes 3,333,000 shares issuable under a warrant exercisable in full within 60 days. Each reporting person reports shared voting and dispositive power and disclaims beneficial ownership except for shares owned of record. The 6.90% calculation uses 85,706,263 shares outstanding as of October 30, 2026, as reported by the issuer.
Filing Explained
This amendment is Schedule 13D, following a Nov. 13 Schedule 13G/A; the supplied definition describes 13D as the category for holders who may seek to influence control, unlike passive-holder 13G.
Sources and calculations
- Senti Biosciences Holdings, Inc. Schedule 13D/A (2026-11-18)
- Senti Biosciences Holdings, Inc. Schedule 13G/A (2026-11-13)
- Schedule 13D/13G purpose (undated)
Key Figures
Key Terms
beneficial ownership regulatory
Warrant technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership did Bayer HealthCare LLC, Bayer US Holding LLC, and Priyal Patel report in SNTI?
AI-generated analysis. How Rhea-AI works. Not financial advice.